FT : Why Russia is pushing into Africa’s nuclear energy market

Why Russia is pushing into Africa’s nuclear energy market
Moscow has been quick to pledge its support to African countries with nuclear energy ambitions

Oil prices edged up yesterday as Iran blamed Israel for a deadly attack on its Damascus consulate, ratcheting up tensions in the region. US benchmark West Texas Intermediate gained about 1 per cent to settle at $83.71 a barrel, its highest level since October. Brent crude, the international marker, rose by a similar margin to settle at $87.42/b.

For decades, Gulf states have built their wealth on plentiful oil and gas reserves, which have powered the global economy. But as the world targets an energy transition away from fossil fuels, countries in the region are diversifying their economies and investing in new industries, including mining.

My Financial Times colleagues Harry Dempsey and Chloe Cornish report on the Gulf states’ increasing investment in the resources needed to produce clean energy. For some resource-rich nations in Africa, Asia and Latin America, the entrance of these middle powers into the critical minerals battleground is a welcome alternative to decades of exploitative arrangements underpinned by either western colonialism or Chinese debt.

Our main item today focuses on how Rosatom, Russia’s state-owned nuclear giant, is making strides to export its technology and build plants in the global south. As Rob Rose reports, the company is targeting Africa in a strategy that presents strategic challenges for the US and other western nations.

Thanks for reading,

Jamie

Russia, hedging against nuclear sanctions, courts Africa
As the sabre-rattling over possible sanctions against Russia’s nuclear industry intensifies, the country’s state-owned energy company Rosatom is busily drumming up new business in Africa. 

Last month, speaking at the African Energy Indaba in Cape Town, Rosatom’s chief executive for central and southern Africa, Ryan Collyer, urged the continent’s most industrialised country, South Africa, to press go on its nuclear programme to ensure “stable, affordable and environmentally friendly” power.

It was a message that resonated with South Africa’s energy minister Gwede Mantashe, who said the country, which has been battling electricity blackouts for the past 16 years, expects nuclear energy to be part of the fix. 

“The proposal to develop 2,500MW of nuclear power is not a dream — there’s already an agreement, and the procurement capacity is being worked on. We’re going to be investing in that capacity,” he told the conference.

While nuclear power provides about 10 per cent of electricity generated globally, according to the Paris-based International Energy Agency, the Koeberg plant in Cape Town is the only nuclear power station on the African continent.

Yet a number of African countries have announced plans to build nuclear power plants in the past year — including Uganda, Rwanda and Kenya.

Russia, sensing an opportunity to forge new economic alliances to mitigate the impact of western sanctions imposed as a result of Vladimir Putin’s February 2022 full-scale invasion of Ukraine, has been quick to pledge its support to African countries with nuclear energy ambitions.

Mantashe said nuclear energy will be “part of the solution” to filling Africa’s energy gap. Last year, research presented at the UN put the number of people without electricity in sub-Saharan Africa at 598mn — nearly half the region’s population.

“African nations are going to be investing more in gas infrastructure and expanding nuclear access,” said Mantashe. 

Rosatom believes it can capture a significant slice of this market — speaking in Russia’s parliament this month, the group’s director-general Alexey Likhachev said he considered Africa a “point of growth” for nuclear technology.

Last week, Rosatom announced it had signed nuclear energy “co-operation” agreements with Mali, Burkina Faso and Algeria during the two-day Atomexpo energy conference, held in the Russian city of Sochi. This entrenched an earlier agreement, announced in October, in which Rosatom said it would build a nuclear power station in Burkina Faso, a country in which the World Bank estimates only 19 per cent of the population has electricity.

And in January, Rosatom announced that construction had begun on the fourth reactor at the $30bn El Dabaa nuclear power plant in Egypt, about 300km from Cairo, which has been billed as one of the two largest nuclear construction projects in the world.

Reducing dependence
Russia’s frenetic push into African markets comes as calls intensify to institute sanctions on Rosatom, including from several EU countries, in response to Putin’s war in Ukraine.

Last week, Belgian Prime Minister Alexander De Croo told the FT that the EU must wean itself off Russian nuclear fuel “as fast as possible” to ensure the bloc doesn’t further boost Putin’s war chest. 

Yet this goal is fraught with difficulty, given Rosatom’s centrality in the global nuclear energy chain. As it is, Rosatom supplies more than a fifth of the enriched uranium fuel used to power nuclear reactor fleets in the US and Europe, and as much as half of the needs of countries such as Hungary.

Rosatom’s Likhachev has fought back, describing calls in Europe and the US for greater sanctions as “short-sighted”, since it increases the price for nuclear fuel in their own countries.

“The US itself has announced plans to close access to its market for our products in a few years. Similar initiatives are being voiced in the EU. Market prices are moving up based on expectations of a negative scenario,” he said in a February interview with Russian state news agency Tass. 

Likhachev said the result is that energy companies from the US and EU will be “forced to buy uranium products at a higher price on the market”. 

This illustrates how Rosatom’s global influence — and the assistance it has provided to foreign governments in building nuclear plants — has provided a significant source of soft power for Putin.

“Nuclear technologies tend to lock in diplomatic ties in a way that other energy sources don’t,” Kevin Book of ClearView Energy Partners, a Washington-based independent research group, told the FT in January. 

Hartmut Winkler, professor of physics at the University of Johannesburg, wrote in December of the danger of African countries borrowing money from Russia to develop nuclear plants. Egypt, for example, borrowed $25bn from Russia to build the El Dabaa power station, which is meant to be paid off over 35 years at a 3 per cent interest rate per year.

“The drawback is that the country develops a strong long-term dependence on Russia to meet one of its most basic needs: electricity provision,” he wrote. The fallout from the Ukraine war could then lead to “disruption and ultimate termination of projects already in place”, given that it typically takes more than a decade to build a nuclear plant.

In South Africa, the relationship with Rosatom has proven particularly controversial.

In 2014, the Russian agency signed a broad “intergovernmental agreement” to build eight nuclear reactors, which would provide 9.6GW of power to South Africa, at an estimated cost of R1tn ($76bn). But this deal, which reports said was directly negotiated between South Africa’s former leader Jacob Zuma and Putin, was later scrapped by the courts amid widespread corruption claims.

Rosatom’s high-profile charm offensive at the African Energy Indaba last month suggests that relationship hasn’t been irrevocably tainted. 

That courtship took another step forward last week, as South Africa’s state-run power company Eskom signed a training “action plan” with Rosatom, including skills sharing at universities and the “secondment of engineering competencies”. 

Russia is betting on these training partnerships as part of a bid to ensure countries from the Brics group are at the forefront of the global move away from fossil fuels. These emerging-market countries are expected to account for 41 per cent of global energy production and consumption by 2040, Rosatom’s executive Evdokiya Polyakovskaya said at the Indaba.

>>> US Research Calls

Research Calls I
  • Upgrades:
    • AN2 Therapeutics (ANTX) upgraded to Mkt Outperform from Mkt Perform at JMP Securities; tgt $6
    • Array Tech (ARRY) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $18
    • Blue Owl Capital (OWL) upgraded to Buy from Neutral at UBS; tgt raised to $22
    • Brown-Forman (BF.B) upgraded to Neutral from Sell at Citigroup; tgt $52
    • Eaton (ETN) upgraded to Equal Weight from Underweight at Barclays; tgt raised to $300
    • Estee Lauder (EL) upgraded to Buy from Neutral at Citigroup; tgt raised to $175
    • Home Depot (HD) upgraded to Outperform from Neutral at Zelman
    • McCormick (MKC) upgraded to Buy from Hold at Argus
    • Moody's (MCO) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $450
    • National Grid (NGG) upgraded to Outperform from Underperform at Exane BNP Paribas
    • StoneCo (STNE) upgraded to Outperform from Neutral at Bradesco BBI
  • Downgrades:
    • BCE Inc (BCE) downgraded to Market Perform from Outperform at BMO Capital Markets
    • Biomea Fusion (BMEA) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $14
    • Blackstone (BX) downgraded to Neutral from Buy at UBS; tgt lowered to $135
    • Century Communities (CCS) downgraded to Underperform from Neutral at Wedbush; tgt lowered to $82
    • Clorox (CLX) downgraded to Neutral from Buy at Citigroup; tgt lowered to $165
    • FIGS, Inc. (FIGS) downgraded to Underperform from Neutral at BofA Securities; tgt lowered to $4.50
    • Lennar (LEN) downgraded to Underperform from Neutral at Wedbush; tgt $144
    • LGI Homes (LGIH) downgraded to Underperform from Neutral at Wedbush; tgt lowered to $74
    • Lowe's (LOW) downgraded to Neutral from Outperform at Zelman
    • Meritage (MTH) downgraded to Underperform from Neutral at Wedbush; tgt lowered to $148
    • Microvast (MVST) downgraded to Neutral from Buy at Janney
    • Nextracker (NXT) downgraded to Equal Weight from Overweight at Barclays; tgt raised to $63
    • NIO (NIO) downgraded to Underweight from Equal Weight at Barclays; tgt $4
    • Petco Health and Wellness (WOOF) downgraded to Underperform from Buy at BofA Securities; tgt lowered to $1.50
    • Porsche (POAHY) downgraded to Neutral from Buy at UBS
    • Ultrapar Participacoes (UGP) downgraded to Market Perform from Outperform at Itau BBA
  • Others:
    • Annaly Capital Mgmt (NLY) initiated with a Buy at Compass Point; tgt $22
    • Grindr (GRND) initiated with a Mkt Outperform at JMP Securities; tgt $14
    • Marqeta (MQ) initiated with a Buy at Monness Crespi & Hardt; tgt $7.50
    • Mineralys Therapeutics (MLYS) initiated with a Buy at Goldman; tgt $30
    • MoonLake Immunotherapeutics (MLTX) initiated with a Neutral at Goldman; tgt $62
    • Olema Pharmaceuticals (OLMA) initiated with a Buy at Goldman; tgt $24
    • Otis Worldwide (OTIS) initiated with a Hold at Melius
    • PowerFleet (PWFL) initiated with an Outperform at Raymond James; tgt $7
    • Q32 Bio (QTTB) initiated with an Overweight at Piper Sandler; tgt $45
    • Rocket Pharmaceuticals (RCKT) initiated with a Neutral at Goldman; tgt $39
    • Solventum Corporation (SOLV) initiated with a Hold at Edward Jones
    • Zebra Tech (ZBRA) initiated with an Equal Weight at Barclays; tgt $292

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • PVH -21.2%, ASTS -10.3%
Other news:
  • ACOR -75.1% (Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement)
  • GRTS -38.3% (positive data from Phase 2 study; prices $32.5 million offering)
  • VERV -34.9% (Updates on its PCSK9 Program)
  • GOEV -27.6% (identifies doubt about continuing as a going concern; reports earnings; enters a $30 billion market with multiple commercial vehicle sales in Saudi Arabia) OCGN -7.8% (Announces Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease)
  • CIFR -7% (March operational update)
  • CVS -5.4% (Medicare Advantage rate update)
  • UNH -4.2% (Medicare Advantage rate update)
  • ELV -3.8% (Medicare Advantage rate update)
  • VEEV -3.1% (CFO departing)
  • CNC -2.8% (Medicare Advantage rate update)
  • DJT -1.9% (files 10K with FY23 earnings)
  • SNDA -1.7% (entered into $75 mln At-The-Market Issuance Sales Agreement)
  • ITCI -1.5% (provides patent updates)
  • MOH -1.2% (Medicare Advantage rate update)
  • WHR -1% (completes major milestone in its portfolio transformation with closing of EMEA transaction)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • SRG +1.7%, MEG +0.8% (guidance)
Other news:
  • PIK +54.7% (enters into merger agreement with Nina Footwear)
  • STRO +6.7% (Sutro Biopharma and Ipsen Pharma SAS (IPSEY) entered into an Exclusive License Agreement; prices an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18/share)
  • ROIV +5.7% (Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million)
  • RIG +4.7% (contract extension worth $195 mln)
  • CRON +3.4% (FL Supreme Court allowing marijuana vote on ballot, according to Orlando Sentinel)
  • SIGA +2.4% (amends agreement with Meridian Medical Technologies)
  • CGC +2.4% (FL Supreme Court allowing marijuana vote on ballot, according to Orlando Sentinel)
  • ACB +2.3% (FL Supreme Court allowing marijuana vote on ballot, according to Orlando Sentinel)
  • NOK +2% (completes sale of platform businesses to Lumine Group)
  • TNDM +2% (FDA clears 510(k) application for insulin pump)
  • UMH +1.9% (increases dividend)
  • ANGO +1.4% (settle litigation with Becton, Dickinson and Company)
  • EYPT +1.4% (Expands Scientific Advisory Board with World-Renowned Retina Specialists)
  • LECO +1.3% (acquires RedViking)
  • SWK +1% (completes sale to Epiroc AB)
  • PSX +1% (expands commercial scale production of renewable diesel)
  • SNDL +1% (SNDL and Nova Cannabis Announce Assignment of Dutch Love Stores to Nova Cannabis and Extension of Credit Facility)
  • RCKT +1% (receives EMA acceptance of RP-L102 Marketing Authorization Application for the treatment of fanconi anemia)

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • PIK +69%, ANGO +7%, CGC +6.8%, ACB +4.6%, RCKT +4.1%, RIG +3.6%, SIGA +2.5%, MJ +2.2%, TLRY +2.1%, NOK +2%, TNDM +2%, UMH +1.9%, SRG +1.7%, SNDL +1.5%, LECO +1.3%, RKLB +1%, CRON +0.8%, PSX +0.7%, UBS +0.7%
  • Gapping down:
    • ACOR -60.1%, GRTS -33.6%, GOEV -24.3%, PVH -22.2%, CVS -6.1%, OCGN -5.8%, CIFR -5.7%, ASTS -5.7%, ELV -4.2%, UNH -3.8%, MOH -2.4%, CNC -2.1%, STRO -1.8%, DJT -1.7%, VEEV -1.3%

Challenges : Pourquoi la cession du Club Med est en panne ?

Pourquoi la cession du Club Med est en panne ?

EXCLUSIF – Malgré l’ouverture du capital du Club Med il y a un an par son actionnaire majoritaire, le groupe Fosun, l’opération tarde toujours à se mettre en place. L’annonce triomphale des bons résultats de l’entreprise a paradoxalement refroidi les investisseurs potentiels qui considèrent qu’on leur en demande un prix beaucoup trop élevé.

C’est un feuilleton qui passionne les banquiers d’affaires un brin désœuvrés ces derniers temps, mais aussi les fonds d’investissement, les milieux politiques parisiens, les journalistes, les élus locaux… Bref, toute une brochette de « GNM », les « gentils non-membres » comme on pourrait les appeler en reprenant la célèbre terminologie du Club Med.

Le « Club », fleuron du tourisme français devenu chinois en 2015, distingue depuis les années 1960 ses « GO » (pour gentils organisateurs : ses salariés), de ses GM (les gentils membres : les clients) et même depuis quelques années ses « GE » (gentils employés, une seconde catégorie de salariés qui ne sont pas considérés comme des organisateurs et sont le plus souvent soumis à des contrats de travail locaux).

L’affaire qui agite tout ce beau monde est l’ouverture du capital du Club Med par son actionnaire majoritaire, le groupe Fosun. Ce conglomérat présent dans l’assurance et les loisirs entre autres, est contraint de se séparer de nombreuses activités en raison d’un endettement très important. Mais contrairement à d’autres activités déjà vendues, ou en cours de cession, Fosun souhaite rester actionnaire majoritaire du Club Med, en cédant seulement 30 % du capital à un investisseur qui n’aurait pas voix au chapitre sur la stratégie et la conduite du voyagiste. Cela fait plus d’un an que l’opération a été annoncée et lancée, mais elle tarde bigrement à se concrétiser.

Départ de l’actionnaire chinois
Un moment chargé de trouver de nouveaux investisseurs, candidats à une participation minoritaire, le président du Club, Henri Giscard d'Estaing avait constitué un tour de table avec l’aide de la banque Lazard. Mais l’actionnaire chinois n’a pas approuvé le montage proposé par son représentant en France et lui a même retiré le dossier comme Challenges l’avait révélé en décembre 2023.

L’entreprise s’est efforcée de minimiser ce qui pouvait être interprété comme un désaveu mais il n’en reste pas moins vrai que dans la foulée, Giscard Junior, 68 ans cette année, a quitté ses fonctions d’administrateur exécutif, vice-président du conseil d’administration, membre du comité stratégique et du comité environnemental, social et de gouvernance du conseil d’administration de Fosun Tourism. Il en reste codirecteur général et président du Club Med.

Bank of America à la manœuvre
D’après les informations de Challenges, des discussions assez avancées ont eu lieu par l’intermédiaire des représentants de la nouvelle banque d’affaires mandatée par Fosun, Bank of America. Le fonds d’investissement souverain saoudien Public Investment Fund (PIF), qui pèse près de 800 milliards de dollars et prévoit d’arriver à 2 000 milliards en 2030 via ses acquisitions remarquées dans les loisirs notamment (Nintendo, Electronic Arts, le club de foot anglais de Newcastle…) fait partie des investisseurs potentiels. Comme le révélaient également Les Echos, en janvier, la holding de la famille suisse Maus, qui détient Lacoste et Aigle, s’est aussi manifestée. Plusieurs autres fonds originaires du Golfe se sont déclarés intéressés tels que le fonds d’investissement souverain d’Abou Dabi. Mais toutes ces marques d’intérêt se sont heurtées à un obstacle de poids : le prix demandé par le vendeur chinois pour une participation minoritaire.

En annonçant triomphalement qu’il a réussi un exercice 2023 historique avec des revenus record, Giscard n’a pas aidé à la bonne sérénité des négociations, explique un proche du dossier. Car ces bons résultats contribuent à relever la valorisation d’une entreprise que les parties prenantes considèrent comme déjà beaucoup trop chère. » Selon nos informations, les discussions sont aujourd’hui au point mort malgré le nombre non négligeable de marques d’intérêt.

Les vendeurs ont fixé une valeur d’entreprise à 2 milliards d’euros, ce qui correspond exactement au chiffre d’affaires annuel. Les experts du tourisme estiment cette valorisation beaucoup trop élevée pour une entreprise qui ne réalise que 90 millions d’euros de résultat net. Le management de l’entreprise étant détenteur d’une partie des actions (moins de 1 % selon la direction du Club Med), il a tout intérêt à gonfler la valeur de son patrimoine, surtout si cela risque constituer sa « prime de départ ».

Enjeux diplomatiques et économiques
« Les investisseurs potentiels ne sont pas prêts à payer si cher pour rester un actionnaire dormant, assure cet expert. La pression est de plus en plus forte sur Fosun pour qu’il cède la majorité mais la présidence du groupe chinois n’a pas encore renoncé à ses exigences. » Selon ce même initié, en toute logique les discussions ne peuvent qu’aboutir à une vente de la totalité du capital du Club Med car « Fosun a un très gros besoin de cash compte tenu de son endettement ». Voilà pourquoi l’affaire est au point mort mais devrait ne pas y rester indéfiniment.

L’affaire est surveillée par l’Elysée et Bercy comme le lait sur le feu. En préférant tel ou tel fonds du Moyen Orient, on espère faire d’une pierre deux coups au sommet de l’Etat, économique et diplomatique. Plus sensible encore, le poids économique du Club Med dans les stations de montagnes des Alpes, dont il est un moteur de développement, a incité la BPI à vouloir s’inviter dans le futur tour de table. Idem pour la Caisse des dépôts et consignations, le bras armé de l’Etat, qui se sent particulièrement concerné via sa filiale la Compagnie des Alpes (opérateur des remontées mécaniques et investisseur hôtelier à la montagne) et la Banque des Territoires, qui est propriétaire immobilier de plusieurs sites exploités par le Club Med.

>>> Europe : Brokers Upgrades & Downgrades - 2nd of April 2024 V2(+)

>>> Up
* Adyen Raised to Outperform at Evercore ISI; PT 1,850 euros
* A.G. Barr PT Raised to 700 pence from 600 pence at Peel Hunt
* Aker Carbon Capture Raised to Neutral at SpareBank; PT 10 kroner
* Aker Carbon Capture Raised to Buy at Fearnley; PT 10 kroner (+)
* Barclays PT Raised to 330 pence from 220 pence at Jefferies
* BE Semiconductor Raised to Overweight at Barclays; PT 175 euros
* ConvaTec Raised to Buy at HSBC; PT 350 pence
* Duell Raised to Buy at Evli Bank; PT 4 euro cents
* Eli Lilly PT Raised to $895 from $675 at Citi
* Embracer Raised to Buy at ABG; PT 29 kronor
* Krones Raised to Buy at Berenberg; PT 154 euros
* National Grid Raised to Outperform at BNPP Exane; PT 1,250 pence (+)
* RWE Cut to Neutral at BNPP Exane; PT 34.20 euros (+)
* TechnipFMC PT Raised to $30 from $25 at Benchmark

>>> Down
* Aixtron Cut to Equal-Weight at Barclays; PT 30 euros
* IO Biotech Cut to Neutral at Kempen & Co (+)
* IVS Group Cut to Hold at Equita; PT 6.70 euros (+)
* Munters Downgraded to Hold at Berenberg on Inflated Valuation
* Rational Cut to Equal-Weight at Barclays; PT 834 euros
* Seche Environnement SACA Cut to Add at IDMidcaps; PT 115 euros (+)
* Tethys Oil Cut to Neutral at SpareBank; PT 45 kronor

>>> Initiation
* Caledonia Mining Reinstated Buy at Liberum; PT 1,163 pence
* Crocs Rated New Overweight at Barclays; PT $167
* Deckers Outdoor Reinstated Overweight at Barclays; PT $1,110
* GE Vernova Rated New Neutral at JPMorgan; PT $141
* GE Vernova Rated New Outperform at RBC; PT $160
* Glanbia Rated New Buy at Mizuho Securities; PT 26 euros
* On Holding Rated New Overweight at Barclays; PT $38
* Skechers USA Rated New Overweight at Barclays; PT $71

>>> Call
* Barclays PT Now a Street-High at Jefferies on Returns Potential
* BofA Stock Indicator Says Sentiment Is ‘Nowhere Near Euphoria’
* Barclays Expands Footwear Coverage, Bullish on Crocs, Skechers
* Goldman Takes S&P 500 Valuations Off of Worry List: Taking Stock
* Krones Backlog Brings Stability, Berenberg Upgrades to Buy
* Lonza Appointment of Wienand as CEO Is Positive, Vontobel Says (+)

>>> Stoxx 600 Pre-Market Indications

  • Equinor (DNQ TH) +3%
  • ASML (ASME TH) +2.9%
  • NN Group (2NN TH) +2.8%
  • Barclays (BCY TH) +2.7%
    • Barclays PT Now a Street-High at Jefferies on Returns Potential
  • Leonardo (FMNB TH) +2.2%
  • Vistry Group (44B TH) +2.2%
  • UPM-Kymmene (RPL TH) +2%
  • Repsol (REP TH) +2%
  • Scor (SDRC TH) +1.8%
  • Aixtron (AIXA TH) -1.4%
    • Aixtron Cut to Equal-Weight at Barclays; PT 30 euros
  • Ferrari (2FE TH) -1.5%
  • CRH (CRG TH) -1.5%
  • K+S (SDF TH) -1.8%
  • Salmar (JEP TH) -1.9%
  • Vonovia (VNA TH) -2%
  • Iberdrola (IBE1 TH) -2.2%
  • Andritz (AZ2 TH) -3.1%

>>> TradeGate Pre-Market Indications

DAX:
  • Siemens Energy (ENR TH) +1.3%
  • Infineon (IFX TH) +1%
  • Vonovia (VNA TH) -1.5%
MDAX:
  • Krones (KRN TH) +1.5%
    • Krones Backlog Brings Stability, Berenberg Upgrades to Buy
  • Aroundtown (AT1 TH) -1.2%
    • Aroundtown Announces Debt Exchange Offer
  • Aixtron (AIXA TH) -1.4%
    • Aixtron Cut to Equal-Weight at Barclays; PT 30 euros
  • K+S (SDF TH) -2%
SDAX:
  • Ionos (IOS TH) +5.6%
    • Ionos Gets Up to €410M Contract From German Administration: DPA
  • Adtran Holdings (QH9 TH) +3%
  • Kontron (KTN TH) +2.3%
  • Suess MicroTec (SMHN TH) +2.3%
  • Duerr (DUE TH) -0.8%